CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.
暂无分享,去创建一个
R. Fimmers | F. Tacke | C. Trautwein | C. Strassburg | T. Sauerbruch | J. Trebicka | H. Wasmuth | S. Klein | H. Strunk | C. Meyer | C. Jansen | J. Lehmann | J. Görtzen | M. Berres | S. Asmacher
[1] R. Fimmers,et al. Soluble TNF-Alpha-Receptors I Are Prognostic Markers in TIPS-Treated Patients with Cirrhosis and Portal Hypertension , 2013, PloS one.
[2] R. Moreau,et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. , 2013, Gastroenterology.
[3] G. Kolios,et al. CXCR3 axis in patients with primary biliary cirrhosis: a possible novel mechanism of the effect of ursodeoxycholic acid , 2013, Clinical and experimental immunology.
[4] C. Trautwein,et al. Proapoptotic effects of the chemokine, CXCL 10 are mediated by the noncognate receptor TLR4 in hepatocytes , 2013, Hepatology.
[5] F. Wong,et al. Recent advances in our understanding of hepatorenal syndrome , 2012, Nature Reviews Gastroenterology &Hepatology.
[6] Fabian Kiessling,et al. Chemokine Cxcl9 attenuates liver fibrosis‐associated angiogenesis in mice , 2012, Hepatology.
[7] D. Rockey,et al. Complications of cirrhosis , 2012, Current Opinion in Gastroenterology.
[8] S. Akira,et al. CD44 Participates in IP-10 Induction in Cells in Which Hepatitis C Virus RNA Is Replicating, through an Interaction with Toll-Like Receptor 2 and Hyaluronan , 2012, Journal of Virology.
[9] M. Putt,et al. Serum cytokine profiles associated with early allograft dysfunction in patients undergoing liver transplantation , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[10] R. Stirling,et al. CXCR3 Expression Elevated on Peripheral CD8(+) Lymphocytes from HIV/HCV Coinfected Individuals. , 2011, Viral immunology.
[11] T. Sauerbruch,et al. Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt , 2011, European journal of gastroenterology & hepatology.
[12] David L. Thomas,et al. CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis C. , 2011, The Journal of infectious diseases.
[13] F. Tacke,et al. Serum chemokine receptor CXCR3 ligands are associated with progression, organ dysfunction and complications of chronic liver diseases , 2011, Liver international : official journal of the International Association for the Study of the Liver.
[14] U. Panzer,et al. CXCR3 Deficiency Exacerbates Liver Disease and Abrogates Tolerance in a Mouse Model of Immune-Mediated Hepatitis , 2011, The Journal of Immunology.
[15] F. Tacke,et al. Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection , 2011, Hepatology.
[16] C. Trautwein,et al. Functional role of chemokines in liver disease models , 2010, Nature Reviews Gastroenterology &Hepatology.
[17] J. Pfeilschifter,et al. CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation. , 2010, Journal of autoimmunity.
[18] M. O. Rocha,et al. Soluble inflammatory markers as predictors of liver histological changes in patients with chronic hepatitis C virus infection , 2010, European Journal of Clinical Microbiology & Infectious Diseases.
[19] Marianthi Markatou,et al. Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. , 2009, The Journal of infectious diseases.
[20] F. Tacke,et al. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. , 2009, Gastroenterology.
[21] M. Calvino,et al. Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. , 2008, World journal of gastroenterology.
[22] L. Chiriboga,et al. Intrahepatic levels of CXCR3‐associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C , 2008, Hepatology.
[23] A. Rieger,et al. IP-10 Correlates with Hepatitis C Viral Load, Hepatic Inflammation and Fibrosis and Predicts Hepatitis C Virus Relapse or Non-Response in HIV–HCV Coinfection , 2008, Antiviral therapy.
[24] F. Gao,et al. CXCL10 regulates liver innate immune response against ischemia and reperfusion injury , 2007, Hepatology.
[25] K. Tsuneyama,et al. Increased levels of chemokine receptor CXCR3 and chemokines IP-10 and MIG in patients with primary biliary cirrhosis and their first degree relatives. , 2005, Journal of autoimmunity.
[26] S. McColl,et al. Expression of the CXCR3 ligand I‐TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation , 2004, Hepatology.
[27] Rakesh K. Kumar,et al. Expression of the chemokine IP‐10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation , 2003, Journal of leukocyte biology.
[28] C. García-Monzón,et al. Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease , 2002, American Journal of Gastroenterology.
[29] F. Marra,et al. Chemokines in liver inflammation and fibrosis. , 2002, Frontiers in bioscience : a journal and virtual library.
[30] Xiaodan Ren,et al. CXC Chemokine Expression After Stimulation with Interferon-&ggr; in Primary Rat Hepatocytes in Culture , 2002, Shock.
[31] P. Raab,et al. Hemodynamic Effects of Propranolol and Nitrates in Cirrhotics with Transjugular Intrahepatic Portosystemic Stent-Shunt , 2002, Scandinavian journal of gastroenterology.
[32] T. Okanoue,et al. Increase of chemokine interferon‐inducible protein‐10 (IP‐10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes , 2001, Clinical and experimental immunology.
[33] H. Schild,et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study , 2000, Gut.
[34] J. Cosín,et al. High plasma CXCL10 levels are associated with HCV-genotype 1, and higher insulin resistance, fibrosis, and HIV viral load in HIV/HCV coinfected patients. , 2012, Cytokine.
[35] D. Lamarre,et al. Targeted impairment of innate antiviral responses in the liver of chronic hepatitis C patients. , 2012, Journal of hepatology.
[36] Chih-Ping Chen,et al. Prognostic Significance of Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor, and Angiogenin in Patients With Resectable Hepatocellular Carcinoma After Surgery , 2003, Annals of Surgical Oncology.
[37] P. Bioulac-Sage,et al. [Mechanisms of hepatic fibrogenesis]. , 2002, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.
[38] J. Bosch,et al. Complications of cirrhosis. I. Portal hypertension. , 2000, Journal of hepatology.